Index

A

Acrolein
non-enzymic oxidation of ARA and, 121–124
See also Enzymic oxidation
Acute neural trauma, see Neurotraumatic disorders
Acyl-CoA
in brain, 64–67
lysophospholipid acyltransferase (ALCAT), 64–67
synthetases (ACSL), 61–63
See also Brain glycerophospholipids; CoA
Adrenoleukodystrophy (ALD), 336–338
X-linked (X-ALD), 337–338
See also Peroxisomal disorders
Adrenomyeloneuropathy, 339
Advanced glycation end products (AGEs)
receptor for (RAGE), 228
See also neurodegenerative diseases
Age-related macular degeneration (AMD)
DHA for treating, 340
See also Brain ageing; Peroxisomal disorders
Aggressive disorders
n–3 and n–6 fatty acids effect on, 313
See also Neuropsychiatric disorders
Aging
defined, 187
See also Brain aging
ALA (alpha-linolenic acid)
DHA biosynthesis in liver and, 55–57
fish oil effects on brain, 367
in neurotraumatic disorders (spinal cord injury), 274
incorporation in glycerophospholipids, 67–68
transport to brain, 48–51
See also DHA (docosahexaenoic acid); EPA (eicosapentaenoic acid)
Alzheimer disease (AD)
DHA importance in diet and, 232–238
genetic and environmental factors, 224–225
interactions among excitotoxicity, oxidative stress, and neuroinflammation in, 244–248
See also Parkinson disease (PD)
Amyotrophic lateral sclerosis (ALS)
DHA importance in diet and, 242–244
See also Multiple sclerosis (MS)
Antiarrhythmic effects (fish oil), 11–13
Antiatherosclerotic effects (fish oil), 10–11
Anti-inflammatory effects (fish oil), 10–11
Antisense oligonucleotides, 374–375
Antithrombotic effects (fish oil), 13, 14
Apolipoprotein E (APOE) gene, 224–225
See also Neurodegenerative diseases
Apoptosis
apoptotic cell death in neurodegenerative diseases, 222–223
DHA role in modulation of, 164–166
ARA (arachidonic acid)
biosynthesis in liver, 58–59
brain aging and, 191–193
enzymic oxidation in brain
cis-EET acids, 118
COX, 108–110
eicosanoids in brain (TX), 110–112
EPOX, 116–117
lipoxins, 113–116
LOX, 112–113
fish oil effects on brain and, 367–368
in ALS, 242
in ischemic injury, 266–270
ARA (arachidonic acid) (cont.)
in neural membranes, 53–54
in neuropsychiatric disorders
ADHD, 313
aggressive disorders and cocaine addiction, 313
DHA abnormalities levels, 303–304
in neurotraumatic disorders
spinal cord injury, 275
incorporation in glycerophospholipids, 60, 70
metabolism, unsolved problems of, 373–374
antisense oligonucleotides development and RNAi, 374–375
characterization of enzymes associated with metabolism, 374
receptors characterization for neuroprotectins and resolvins, 375–376
non-enzymic oxidation in brain
4-HNE, acrolein, and malondialdehyde, 119–124
isofurans, 128
isoprostanes, 124–128
release from cPLA2, 92, 94–95
transport of dietary ARA to brain, 48–51
See also DHA (docosahexaenoic acid); n–6/n–3 ratio
Arthritis
DHA and, 351–354
osteoarthritis, 352
psoriatic, 352
See also Non-neural disorders
Atherosclerosis
defined, 10
See also Amyotrophic lateral sclerosis (ALS); Multiple sclerosis (MS)
Attention-deficit/hyperactivity disorder (ADHD)
n–3 fatty acids
and n–6 fatty acids effect on, 313–314
supplementation effect on (high doses EPA), 316
See also Neuropsychiatric disorders
Autism
glycerophospholipids and fatty acids alterations in, 310–311
See also Neuropsychiatric disorders

B
BDNF (brain-derived neurotrophic factor), 226–228
alterations in spinal cord injury, 272–274
mediated signaling in neuropsychiatric disorders, 299–303
TBI and, 276, 277
See also cAMP; Neurodegenerative diseases
Biosynthesis
n–3 fatty acids in liver
ALA, 55–57
DHA, 55–58
EPA, 57
n–6 fatty acids in liver
ARA, 58–59
LA, 58–59
Bipolar disorders
glycerophospholipids and fatty acids alterations in, 307–309
n–3 fatty acids
and n–6 fatty acids effect on, 311, 312
supplementation effects, 315
See also Autism; Depression; Dyslexia; Schizophrenia
Bleeding tendency
n–3 fatty acids and, 24
See also Fish oil
Blood pressure
DHA deficiency in brain and, 208
fish oil (n–3 fatty acids), 24–25
Brain, 47
DHA role in, 151
apoptosis, 164–166
docosanoids generation, 166
enzymic activities modulation, 159–160
gene expression modulation, 158–159
inflammation and immunity modulation, 161–162
learning and memory, 163–164
membranes’ physiochemical properties modulation, 156–157
neurite outgrowth generation, 166–168
neurotransmission modulation, 157–158
nociception (pain) modulation, 168–169
plasma membrane targeting and raft formation, 169
visual function modulation, 168
EPA role in, 151, 170
depression modulation, 172
enzymic activities modulation, 174
gene expression modulation, 173–174
inflammation and immunity modulation, 171–172
lipid rafts modulation, 176
resolving E1 generation, 174–176
fish oil effects on
ion channels, 17–18
neural membranes, 16–17
neuritogenesis, 17
receptors, 18
olive oil effects on, 29–31
oxidation in (enzymic)
ARA, 108–118
DHA, 129–133
eicosanoids in brain, 110–112
EPA, 136–138
oxidation in (non-enzymic)
ARA, 119–128
DHA, 133–136
EPA, 138–139
See also Heart; n–3 fatty acids; n–6 fatty acids
Brain aging, 189–209
DHA
and ARA entry and metabolism in developing brain, 191–193
in phosphatidylserine (PtdSer), 194–199
in plasmalogen, 194–196
levels alterations in various regions during aging, 193–194
DHA deficiency in brain, consequences of, 199–208
effects on behavioral parameters, 201
effects on blood pressure, 208
effects on glucose utilization, 201–202
effects on growth factors, 206–207
effects on ion channels permeability, 207–208
effects on lipid metabolism, 202
effects on protein function and enzyme activities, 203–204
effects on receptor function, 203–205
Brain glycerophospholipids, 47
alterations in neurotraumatic disorders
epilepsy, 277–278
ischemic injury, 266–270
kainic acid (KA) induced neural cell injury, 279
spinal cord injury, 272–274
TBI, 275
alterations in neuropsychiatric disorders
autism, 310–311
bipolar disorders, 307–309
depression, 307–309
dyslexia, 309–310
schizophrenia, 304–306
ARA in neural membranes, importance of, 53–54
DHA in neural membranes, importance of, 51–53
fatty acids incorporation in, 60–70
ACSL, 61–63
ALA, 67–68
ALCAT in brain, 64–67
ARA, 70
CoA-independent reacylation in brain, 67
DHA, 68–70
LA, 67–68
fatty acids release from, 79
ARA release from cPLA2, 92, 94–95
cPLA2 in bovine brain, 92–95
cPLA2 regulation, 97–98
DHA release from PlsCho-PLA2, 88–89
DHA release from PlsEtn-PLA2 in brain, 81–88
DHA release from PlsEtn-PLA2 in kidney, 89–91
DHA release from PtdSer, 91
PLA2 in rat brain, 96
PlsEtn-PLA2 regulation, 96–97
receptor-mediated degradation of plasmalogens, 91–92
fatty acids transport to brain
ALA, 48–51
ARA, 48–51
DHA, 48–51
LA, 48
See also Neural membranes
C
Caloric restriction (CR)
neurodegenerative diseases and, 228–230
See also Neural disorders
cAMP
alterations in spinal cord injury, 272–274
TBI and, 276
See also BDNF (brain-derived neurotrophic factor)
Choline plasmalogen
PslCho-PLA$_2$ in canine myocardium, 88–89
See also Ethanolamine plasmalogen

Chronic diseases
and dietary $n$–6/$n$–3 ratio, 368–371
See also Neural disorders; Non-neural disorders

Chronic obstructive pulmonary disease (COPD)
clinical trials in, 356
DHA and, 344–346

CoA
independent reacylation in brain, 67
See also Acyl-CoA; Brain glycerophospholipids

Cocaine addiction
$n$–3 and $n$–6 fatty acids effect on, 313
See also Neuropsychiatric disorders
cPLA$_2$
ARA release from, 92–95
in bovine brain, 92–95
regulation, 97–98
See also Choline plasmalogen; Ethanolamine plasmalogen

CREB, 301–303
See also Neuropsychiatric disorders

Crohn’s disease (CD)
clinical trials in, 356–357
DHA and, 346, 347

Cystic fibrosis (CF)
clinical trials in, 356
DHA and, 348–351

Cyclooxygenases (COX)
DHA role in enzymic activities modulation, 159
enzymic oxidation of ARA and, 108–110
EPA role in modulation of, 176
isoforms in brain, 108–110
See also Epoxigenases (EPOX); Lipoxygenases (LOX)

Cytochromes P450 (CYP450)
epoxigenases (EPOX), 116–117
See also Cyclooxygenases (COX)

D
Depression
EPA role in modulation of, 172
glycerophospholipids and fatty acids alterations in, 307–309
major depressive disorder (MDD), 308
$n$–3 fatty acids
and $n$–6 fatty acids effects, 311–312
supplementation effects, 315–317
See also Autism; Bipolar disorders; Dyslexia; Schizophrenia

DHA (docosahexaenoic acid)
biochemical activities comparison with EPA, 152–156
biosynthesis in liver, 55–58
brain aging and alterations in DHA levels, 193–194
deficiency consequences, 199–208
DHA in phosphatidylserine (PtdSer), 194–199
DHA in plasmalogens, 194–196
entry and metabolism in developing brain, 191–193
clinical trials in chronic diseases, 356–357
enzymic oxidation in brain, 129
17S D series resolvins, 130
docosatrienes, 131–133
fish oil effects on brain, 367
in ALS, 242–244
in Alzheimer disease (AD), 232–238
in Huntington disease (HD), 244
in neural membranes, 51–53
in neuropsychiatric disorders
ADHD, 314
aggressive disorders and cocaine addiction, 313
bipolar disorder, 315
depression, 315
DHA abnormalities levels, 303–304
in neurotraumatic disorders
epilepsy, 278–279
ischemic injury, 270–272
kainic acid (KA) induced neural cell injury, 280–281
spinal cord injury, 274
in Parkinson disease (PD), 238–242
incorporation in glycerophospholipids, 68–70
metabolism, unsolved problems of, 373–376
antisense oligonucleotides development and RNAi, 374–375
characterization of enzymes associated with metabolism, 374
receptors characterization for neuroprotectins and resolvins, 375–376
multiple sclerosis and, 342–343
non-enzymic oxidation in brain 4-HHE, 133–134
neurofurans, 136
neuroketals, 135
neuroprostanes, 134–135
non-neural diseases and, 343–344
arthritis, 351–354
COPD, 344–346
Crohn’s disease (CD), 346–347
cystic fibrosis (CF), 348–351
DHA and clinical trials in chronic diseases, 356–357
osteoporosis, 354–355
psoriasis, 355–356
SLE, 347–348
peroxisomal disorders treatment and, 338
adrenomyeloneuropathy, 339
retinitis pigmentosa (RP), 339–340
retinopathy, 339–340
prion diseases and, 340–342
release from plasmalogen
PlsCho-PLA₂ in canine myocardium, 88–89
PlsEtn-PLA₂ in bovine brain, 81–88
PlsEtn-PLA₂ in rabbit kidney, 89–91
receptor-mediated degradation of plasmalogens, 91–92
release from PtdSer, 91
role in brain, 151
apoptosis, 164–166
docosanoids generation, 166
enzymic activities modulation, 159–160
gene expression modulation, 158–159
inflammation and immunity modulation, 161–162
learning and memory, 163–164
neurite outgrowth generation, 166–168
neurotransmission modulation, 157–158
nociception (pain) modulation, 168–169
physiocochemical properties modulation of membranes, 156–157
plasma membrane targeting and raft formation, 169
visual function modulation, 168
transport of dietary DHA to brain, 48–51
See also ALA (alpha-linolenic acid); ARA (arachidonic acid); EPA (eicosapentaenoic acid); n-6/n-3 ratio

Docosanoids
DHA role in generation of, 166
See also DHA (docosahexaenoic acid);
Eicosanoids
Docosatrienes
enzymic oxidation of DHA, 131–133
See also Non-enzymic oxidation
Dyskinesias
levodopa induced (LIDs), 241
See also n-3 fatty acids
Dyslexia
glycerophospholipids and fatty acids alterations in, 309–310
See also Neuropsychiatric disorders

E
Eicosanoids
enzymic oxidation of ARA and, 110–112
in brain, 110–112
thromboxanes (TX), 110–112
See also Docosanoids; EPA (eicosapentaenoic acid)
Enzyme activities
DHA
deficiency in brain and, 205–206
role in modulation of, 159–160
EPA role in modulation of, 174
Enzymic oxidation
ARA
cis-EET acids, 118
COX, 108–110
eicosanoids in brain, 110–112
EPOX, 116–117
lipoxins, 113–116
LOX, 112–113
DHA, 129
17S D series resolvins, 130
docosatrienes, 131–133
EPA, 136–138
See also Non-enzymic oxidation
EPA (eicosapentaenoic acid)
biochemical activities comparison with DHA, 152–156
clinical trials in chronic diseases, 356–357
DHA biosynthesis in liver, 57
enzymic oxidation in brain, 136–138
fish oil effects on brain, 367
in neuropsychiatric disorders
ADHD, 314
DHA abnormalities levels, 303–304
high EPA doses for treating (ADHD), 316–317
EPA (eicosapentaenoic acid)  
(high EPA doses for treating  
depression, 316)  
in neurotraumatic disorders  
epilepsy, 278  
ischemic injury, 271  
spinal cord injury, 274  
non-enzymic oxidation in brain,  
138–139  
non-neural diseases and, 348  
prion diseases and, 340  
role in brain, 151, 170  
depression modulation, 172–173  
enzyme activities modulation, 174  
gene expression modulation, 173–174  
inflammation and immunity  
modulation, 171–172  
lipid rafts modulation, 176  
resolving E1 generation, 174–176  
See also ALA (alpha-linolenic acid);  
ARA (arachidonic acid); DHA  
(docosahexaenoic acid); n–6/n–3  

Epilepsy  
glycerophospholipids and fatty acids  
alterations in, 277–278  
n–3 fatty acids effect on (DHA), 278–279  
See also Neurotraumatic disorders  
Epoxycosatrenioic acids (EET)  
cis-, 118  
enzymic oxidation of ARA and, 118  
Epoxynogenases (EPOX)  
enzymic oxidation of ARA and, 116–117  
isofomis in brain, 116–117  
See also Cyclooxygenases (COX);  
Lipoxygenases (LOX)  
ERK kinase  
DHA role in enzymic activities  
modulation, 160  
See also Enzyme activities  
Ethanolamine plasmalogen  
PlsEtN-PLA2 in  
bovine brain, 81–88  
in rabbit kidney, 89–91  
regulation, 96–97  
receptor-mediated degradation of, 91–92  
See also Choline plasmalogen  
Excitotoxicity  
interactions with oxidative stress and  
neuroinflammation in  
neurodegenerative diseases, 244–248  
neurotraumatic disorders, 281–283  

F  
Fish oil  
effects on peroxisomes, 333–334  
effects on brain, 367–368  
chronic diseases and dietary n–6/n–3  
ratio, 368–371  
DHA, 367  
genes expression in animals and plants  
and n–6/n–3 ratio, 371–373  
unsolved problems of DHA and ARA  
metabolism, 373–376  
effects on human health (n–3 fatty acids)  
bleeding tendency, 24  
blood pressure, 24–25  
brain, 16–18  
heart, 9–16  
kidney, 19–20  
liver, 22–24  
lungs, 18–19  
plasma lipids, 20–22  
recommendations for intake, 25  
ingredients importance in human diet,  
1, 2  
n–3 fatty acids in fish oil capsules and  
krill oil capliques, 3–7  
n–3-enriched manufactured products,  
3–8  
See also ARA (arachidonic acid);  
DHA (docosahexaenoic acid);  
Olive oil  

G  
Gene expression modulation  
DHA role in, 158, 159  
EPA role in, 173–174  
Glucose utilization  
DHA deficiency in brain and, 201–202  
See also Fish oil  
Glycerophospholipids, see Brain  
glycerophospholipids  

Growth factors  
DHA deficiency in brain and, 206–207  
See also BDNF (brain-derived  
neurotrophic factor); Brain aging  

H  
Heart  
fish oil effects on, 9  
antiarrhythmie effects, 11–13  
antiinflammatory and  
antiatheroslerotic effects, 10–11
antithrombotic effects, 13–14
n–3 index and heart disease, 15–16
revascularization, 14–15
olive oil effects on, 25–29
See also Brain
Heme oxygenase-1 (HO-1), 231
See also Neurodegenerative diseases
High-density lipoprotein (HDL)
olive oil and, 27
trans fatty acids harmful effects on human health, 32
See also Brain glycerophospholipids;
Low-density lipoprotein (LDL)
Huntington disease (HD)
DHA importance in diet, 244
See also Neurodegenerative diseases
Hydroxyhexenal (4-HHE)
non-enzymic oxidation of DHA and, 133–134
See also Enzymic oxidation
Hydroxynonenal (4-HNE)
non-enzyme oxidation of ARA and, 119–124

I
IGF, 226–231
neurodegenerative diseases and
See also Growth factors
Immunity
DHA role in modulation of, 161–162
EPA role in modulation of, 171–172
Inflammation
DHA role in modulation of, 161–162
EPA role in modulation of, 171–172
in neuropsychiatric disorders, 296–297
Ion channels
DHA deficiency in brain and permeability of, 207–208
fish oil effects on, 17–18
Ischemic injury
glycerophospholipids and fatty acids alterations in, 266–270
n–3 fatty acids effect on ischemic injury
DHA, 270–272
EPA, 269
similarities and differences with traumatic neural injuries, 262–266
See also Neurotraumatic disorders;
Traumatic injury
Isofurans, 128
Isoketals (isolevuglandins), 126–128
Isoprostanes, 124–126

K
Kainic acid (KA)
induced neural cell injury
glycerophospholipids and fatty acids alterations in, 279
n–3 fatty acids effect on (DHA), 280–281
See also Epilepsy; Ischemic injury; Spinal cord injury (SCI); Traumatic injury
Kidneys
fish oil effects on, 19–20
See also Brain; Heart
Krill oil
caplques, n–3 fatty acids in, 3–4
purified krill oil preparations availability, 4–7

L
LA (linoleic acid)
biosynthesis in liver, 58–59
incorporation in glycerophospholipids, 67–68
transport to brain, 48
Learning and memory
DHA role in modulation of, 163–164
See also n–3 fatty acids
Levodopa
induced dyskinesias (LIDs), 241
See also n–3 fatty acids
Lipids
fish oil effects on, 20–22
metabolism, DHA deficiency in brain and, 202
rafts
DHA role in modulation of, 169
EPA role in modulation of, 176
See also Brain glycerophospholipids
Lipoxins (LXA4)
enzymic oxidation of ARA and, 113–116
isoforms in brain, 113–116
Lipoxygenases (LOX)
enzymic oxidation of ARA and, 112–113
isoforms in brain, 112–113
See also Cyclooxygenases (COX);
Epoxygenases (EPOX)
Liver
fish oil effects on, 22, 23, 24
n–3 and n–6 fatty acids biosynthesis in, 54–59
See also Brain; Heart; Kidney
Long-term depression (LTD), 163
Long-term potentiation (LTP), 163
Low-density lipoprotein (LDL)
  fish oil effects on, 20, 21, 22
  olive oil and, 27, 31
  trans fatty acids harmful effects on human health, 32
  See also Brain glycerophospholipids; High-density lipoprotein (HDL); Very low-density lipoprotein (VLDL)
Lungs
  fish oil effects on, 18, 19
  See also Brain; Heart; Kidney; Liver

M
Major depressive disorder (MDD), see under Depression
Malondialdehyde
  non-enzymic oxidation of ARA and, 121–124
  See also Enzymic oxidation
Memory
  DHA role in modulation of learning and, 163–164
  See also Brain
Multiple sclerosis (MS)
  DHA and, 342–343
  See also Amyotrophic lateral sclerosis (ALS); Peroxisomal disorders; Prion diseases

N
n–3 fatty acids
  biosynthesis in liver, 55–58
  clinical trials in chronic diseases and, 356–357
  effects on brain, 16–18
  ion channels, 17, 18
  neural membranes, 16, 17
  neuritogenesis, 17
  receptors, 18
  effects on heart, 9–16
  antiarrhythmic effects, 11–13
  antiinflammatory and antiatherosclerotic effects, 10–11
  antithrombotic effects, 13–14
  n–3 index and heart disease, 15–16
  revascularization, 14–15
  effects on human health, 8
    bleeding tendency, 24
    blood pressure, 24–25
    brain, 16–18
    heart, 9–16
    kidneys, 19–20
    liver, 22–24
    lungs, 18–19
    plasma lipids, 20–22
    recommendations for intake of n–3 fatty acids, 25
  effects on neural diseases, 333
    multiple sclerosis, 342–343
    peroxisomal disorders, 334–340
    prion diseases, 340–342
  effects on neurodegenerative diseases, 217–218, 222
    AD, 232–238
    ALS, 242–244
    HD, 244
    PD, 238–242
    importance of, 231–244
  effects on neuropsychiatric disorders
    ADHD, 313–314
    aggressive disorders and cocaine addiction, 313
    depression and bipolar disorder, 311–312
    fatty acid supplementation effects, 315–317
    mechanism of action of fatty acids, 317–319
  effects on neurotraumatic disorders (DHA)
    epilepsy, 278–279
    ischemic injury, 270–272
    kainic acid (KA) induced neural cell injury, 280–281
    spinal cord injury, 274
  effects on neurotraumatic disorders (EPA)
    epilepsy, 278
    ischemic injury, 271
    spinal cord injury, 274
  effects on non-neural diseases, 343–344
    arthritis, 351–354
    COPD, 344–346
    Crohn’s disease (CD), 346–347
    cystic fibrosis (CF), 348–351
    osteoporosis, 354–355
    psoriasis, 355–356
    SLE, 347–348
effects on TBI, 275–277
enriched manufactured products, 3–8
in fish oil capsules and krill oil caplques, 3–7
incorporation in glycerophospholipids, 60
ALA, 67–68
DHA, 68–70
nutrigenomics/nutrigenetics/transcriptomics approaches to, 376–379
release from brain glycerophospholipids
ARA, 92–95
DHA from choline plasmalogen, 88–89
DHA from ethanolamine plasmalogen, 80–92
DHA from PtdSer, 91
receptor-mediated degradation of plasmalogens, 91–92
supplementation effect on bipolar disorder, 315
depression, 315
EPA high doses for ADHD, 316–317
EPA high doses for depression, 316
transport of dietary ARA to brain, 48–51
See also ALA (alpha-linolenic acid); DHA (docosahexaenoic acid); EPA (eicosapentaenoic acid); n–6/n–3 ratio
n–6 fatty acids
biosynthesis in liver, 58–59
effect on neuropsychiatric disorders
ADHD, 313–314
aggressive disorders and cocaine addiction, 313
depression and bipolar disorder, 311–312
incorporation in glycerophospholipids, 60
ARA, 70
LA, 67–68
release from brain glycerophospholipids
cPLA2 in bovine brain, 92–95
PLA2 in rat brain, 96
transport of dietary DHA to brain, 48–51
n–6/n–3 ratio
chronic diseases and dietary, 368–371
genes expression in animals and plants for improving, 371–373
n–9 fatty acids, see Olive oil
Neural disorders
multiple sclerosis (MS), 342–343
peroxisomal disorders, 334–335
adrenoleukodystrophy (ALD), 336–338
DHA for treating, 338
Zellweger syndrome, 335–336
prion diseases
DHA and, 340–342
EPA and, 341
See also Neurodegenerative diseases; Neuropsychiatric disorders; Neurotraumatic disorders; Non-neural disorders
Neural membranes, 47
ARA importance in, 53–54
DHA
importance, 51–53
role in neurotransmission modulation, 157–158
role in physicochemical properties modulation of, 156–157
fish oil effects on, 16–17
See also Brain Glycerophospholipids; Sphingolipids
Neurite outgrowth, 166–168
Neuritogenesis, 17
Neurodegenerative diseases, 215–249
apoptotic cell death in, 222–223
diet and, 228–231
genetic and environmental factors, 224–225
interactions among excitotoxicity, oxidative stress, and neuroinflammation in, 244–248
lifestyle and, 225–228
n–3 fatty acid importance in diet (DHA), 231–232
in AD, 232–238
in ALS, 242, 243
in HD, 244
in PD, 238–242
onset influencing factors, 223–224
See also Neural disorders; Neuropsychiatric disorders; Neurotraumatic disorders; Non-neural disorders
Neurofurans
enzymic oxidation of EPA and, 136–138
non-enzymic oxidation of DHA, 136
EPA, 138–139
Index
Neuroinflammation
interactions with excitotoxicity and oxidative stress in neurodegenerative diseases, 244–248
neurotraumatic disorders, 281–283
See also Neural disorders
Neuroketals, 135
Neuroprostanes (NP), 134–135
Neuroprotectins, 375–376
Neuropsychiatric disorders, 293–321
ADHD
high dose EPA supplementation effect on, 316–317
n–3 and n–6 fatty acids effect on, 313–314
aggressive disorders and cocaine addiction, 313
autism, 310–311
BDNF-mediated signaling in, 299–303
bipolar disorders, 307–308
n–3 fatty acids supplementation effect on, 315
n–3 and n–6 fatty acids effect on, 311–312
depression, 307–308
high dose EPA supplementation effect on, 315–316
n–3 and n–6 fatty acids effect on, 311–312
dyslexia, 309–310
fatty acids and glycerophospholipids abnormalities levels
autism, 310–311
bipolar disorders, 307–308
depression, 307–308
dyslexia, 309–310
schizophrenia, 304–306
genes involvement in, 319
n–3 fatty acids
and n–6 fatty acids effects, 311–313
mechanism of action, 317–319
supplementation effects, 313–315
neuroinflammation in, 296–297
neurotransmission dysregulation in, 297–299
oxidative stress in, 296–297
schizophrenia, 304–306
See also Neural disorders;
Neurodegenerative diseases;
Neurotraumatic disorders;
Non-neural disorders
Neurotraumatic disorders, 261–283
epilepsy, 277–279
interactions among excitotoxicity, oxidative stress, and neuroinflammation in, 281–283
ischemic injury, 266–270
n–3 fatty acids effects, 270–272
similarities and differences with traumatic neural injuries, 262–264
kainic acid (KA) induced neural cell injury, 279–281
n–3 fatty acids effects, 270–281
spinal cord injury
BDNF alterations in, 273–274
cAMP alterations in, 272–273
n–3 fatty acids effects, 274
traumatic injury
similarities and differences with ischemic injury, 262–265
TBI, 275–277
See also Neural disorders;
Neurodegenerative diseases;
Neuropsychiatric disorders;
Neurotraumatic disorders
Nociception (pain), 168–169
Non-enzymic oxidation
ARA
4-HNE, acrolein, and malondialdehyde, 119–124
isofurans, 128
isoketals (isolevuglandins), 126–128
isoprostanes, 124–126
DHA
4-HHE, 133–134
neurofurans, 136
neuroketals, 135
neuroprostanes, 134–135
EPA, 138–139
See also Enzymic oxidation
Non-neural disorders
DHA and, 343, 344
arthritis, 351–353
clinical trials in chronic diseases, 356–357
COPD, 344–346
Crohn’s disease (CD), 346–347
cystic fibrosis (CF), 348–351
osteoporosis, 354–355
psoriasis, 355–356
SLE, 347–348
EPA and SLE, 348
See also Neural disorders
Nutrigenetics, 376–378
Nutrigenomics, 376–378
Nutrigenomics, 376

O
Oleic acid, see Olive oil
Olive oil
effects
beneficial effects, 25
on brain, 29–31
on heart, 25–29
See also Fish oil; n–3 fatty acids
Osteoarthritis, 352
Osteoporosis, 354–355
Oxidation, 105
  enzymic
  ARA, 108–118
  DHA, 129–133
  EPA, 136–138
  non-enzymic
  ARA, 119–128
  DHA, 133–136
  EPA, 138–139
Oxidative stress
in neuropsychiatric disorders, 296–297
interactions with excitotoxicity and neuroinflammation in neurodegenerative diseases, 244–248
neurotraumatic disorders, 281–283
neurodegenerative diseases and, 219–221

P
Pain, see Nociception (pain)
Parkinson disease (PD)
  DHA importance in diet and, 238–242
genetic and environmental factors, 224
interactions among excitotoxicity, oxidative stress, and neuroinflammation in, 247
See also Neurodegenerative diseases
Peroxisomal disorders
  adrenoleukodystrophy (ALD), 336–338
  contiguous gene syndrome, 334–335
  DHA for treating, 338–339
  adrenomyeloneuropathy, 339
  retinitis pigmentosa (RP), 339–341
  retinopathy, 340–341
  fish oil effect on peroxisomes and, 333–334
  peroxisomal enzyme deficiencies, 334–335
  peroxisome biogenesis disorders (PBDs), 334–335
  peroxisomes and, 334–338
  Zellweger syndrome, 335–336
See also Multiple sclerosis (MS); Prion diseases
Phosphatidylserine (PtdSer)
  brain aging and DHA in, 194–199
  DHA release from, 91
See also Plasmalogens
Phospholipase A₂ (PLA₂)
  cytosolic (cPLA₂), 92–98
  in rat brain, 96
  plasmalogen-selective
  PlsCho-PLA₂, 88–89
  PlsEtn-PLA₂, 81–92, 96–97
Plasma lipids
  fish oil effects on
  LDL, 20–22
  VLDL, 20–22
See also Brain glycerophospholipids
Plasma membrane
  DHA role in targeting of, 169
See also Neural membranes
Plasmalogens
  brain aging and DHA in, 194–196
  DHA release from
  choline plasmalogen (PlsCho-PLA₂ in canine myocardium), 88–89
  ethanolamine plasmalogen (PlsEtn-PLA₂ in bovine brain), 81–88
  ethanolamine plasmalogen (PlsEtn-PLA₂ in rabbit kidney), 89–91
  receptor-mediated degradation of plasmalogens, 91–92
  PlsEtn-PLA₂ regulation, 96–97
See also Phosphatidylserine (PtdSer); Phospholipase A₂ (PLA₂)
Prion diseases
  DHA and, 340–342
  EPA and, 341
See also Multiple sclerosis (MS); Peroxisomal disorders
Protein function
  DHA deficiency in brain and, 203–205
See also n–3 fatty acids
Psoriasis
  DHA and, 355–356
  psoriatic arthritis, 352
**R**

Reactive nitrogen species (RNS)
neurodegenerative diseases and, 220–221
*See also* n–3 fatty acids

Reactive oxygen species (ROS), 105, 106
in neurodegenerative diseases, 218–221
in neurotraumatic disorders, 261–262
in spinal cord injury, 272–273
*See also* Oxidation

Receptors
fish oil effects on brain, 18
function and DHA deficiency in brain, 203–204
*See also* Brain

Resolvins
characterization of receptors for, 375–376
D series, 130, 166
EPA role in generation of E1, 174–176
17S D series, enzymic oxidation of DHA and, 130

Retinitis pigmentosa (RP)
DHA for treating, 339–341
*See also* Visual function

Retinopathy, 339–340

Revascularization
defined, 14–15
n–3 fatty acids effect on, 14–15
*See also* Heart

RNAi, antisense oligonucleotides
development and, 374–375

**S**

Schizophrenia
glycerophospholipids and fatty acids alterations in, 304–306
*See also* Autism; Bipolar disorders; Depression; Dyslexia

Sclerosis
amyotrophic lateral (ALS), 242–244
atherosclerosis, 10
multiple (MS), 342–343
*See also* Peroxisomal disorders; Prion diseases

Sphingolipids, 47
*See also* Neural membranes

Spinal cord injury (SCI)
BDNF alterations in, 272–274
cAMP alterations in, 272–273
glycerophospholipids and fatty acids alterations in, 272–273

n–3 fatty acids effect on
ALA, 274
DHA, 274
EPA, 274

Systemic lupus erythematosus (SLE)
DHA and, 347–348
EPA and, 348

Thrombosis
antithrombotic effects of fish oil, 13–14
defined, 13

**T**

Thromboxanes (TX), 109–111
Trans fatty acids
harmful effects on human health, 31–34
*See also* n–3 fatty acids; n–6 fatty acids

Transcriptomics, 376–378

Traumatic injury, 262, 265

TBI
glycerophospholipids and fatty acids alterations in, 275
n–3 fatty acids effect on, 275–277
*See also* Ischemic injury; Neurotraumatic disorders

**V**

Very long-chain fatty acids (VLCFA), 334
adrenoleukodystrophy (ALD) and, 337–339
Zellweger syndrome and, 336
*See also* Peroxisomal disorders

Very low-density lipoprotein (VLDL)
fish oil effects on, 20–22
trans fatty acids harmful effects on human health, 32
*See also* Brain glycerophospholipids

Visual function
DHA role in modulation of, 168
*See also* Retinitis pigmentosa (RP); Retinopathy

Vitagenes (HSP70 and HSP32), 231
*See also* Neurodegenerative diseases

**Z**

Zellweger syndrome
DHA and, 335–336
*See also* Peroxisomal disorders